SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Heart failure linked to heavy energy drink consumption
Fri April 16th - Drinking excessive energy drinks could be linked to a young man’s heart failure, according to doctors who treated a 21-year-old who consumed four cans a day for two years. More
Shift workers' heart health linked to body clock
Fri April 16th - The risk of heart disease becomes greater the more an individual works outside of their natural body clock, new research suggests. More
Infection much greater risk than vaccines for thrombotic events
Fri April 16th - Cerebral venous thrombosis has been a significant complication of COVID-19 at a rate far higher than seen after vaccination, British researchers have reported. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OTHER NEWS FEEDS OF INTEREST
ENGLEMED HEALTH NEWS

Drug combination found to reduce body weight

Monday August 2nd, 2010

A combination of two drugs may be an effective treatment for obesity, researchers have reported.

Professor Frank Greenway of Louisiana State University System, USA, and colleagues tested a treatment of sustained-release naltrexone plus bupropion, predicting it would "produce complementary actions in central nervous system pathways regulating bodyweight".

A total of 1,742 adults with a body mass index of 30 to 45 took part, mostly (85 per cent) women.

They randomly received either 32mg or 16mg of sustained-release naltrexone plus 360mg of sustained-release bupropion in one tablet per day, or placebo. All were prescribed a moderately reduced calorie diet and exercise.

Half the participants continued for 56 weeks. At this point, the average loss of bodyweight was six per cent on the higher dose, five per cent on the lower dose, and one per cent on placebo.

Common side-effects included nausea, headache, constipation, dizziness, vomiting, and dry mouth. Full results appear in the Lancet.

"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity," report the team.

They write that a weight loss of five to ten per cent improved blood sugar control, and reduced the risk of abnormal blood fats and high blood pressure. "This combination improves control of eating and response to food cravings," they add.

But Professor Arne Astrup of the University of Copenhagen, Denmark, points out that the participants' blood pressure and cholesterol was not reduced as much as would be expected.

He writes: "More data are needed to get a better overall assessment of cardiovascular risk of this otherwise promising combination therapy for obesity."

Greenway, F. L. et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, published online July 30, 2010.

Astrup, A. Is cardiometabolic risk improved by weight-loss drugs? The Lancet, published online July 30, 2010.

Tags: Diet & Food | Fitness | Heart Health | North America | Pharmaceuticals

Printer friendly page Printer friendly page

CATEGORIES